



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Collins et al.

Application No. 10/789,400

Filed: February 27, 2004

Confirmation No. 5376

For: RECOMBINANT HUMAN
METAPNEUMOVIRUS AND ITS USE

Examiner: Not yet assigned

Art Unit: 1632

Attorney Reference No. 4239-67784-01

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: MAIL STOP MISSING PARTS, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Agent
for Applicant(s)

Date Mailed June 14, 2004

**INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97(b)(3)**

MAIL STOP MISSING PARTS
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language documents. Applicants respectfully request that these documents be listed as references cited on the issued patent.

If the present application was filed after June 30, 2003, copies of United States patents and United States published patent applications do not have to be provided to the Patent Office. This requirement of 37 C.F.R. § 1.98(a)(2)(i) has been waived by the United States Patent and Trademark Office pursuant to the Official Gazette Notice on August 5, 2003 (1276 OG 55). Applicants will provide copies of such patents upon request.


Applicants filed this Information Disclosure Statement ("IDS") before the mailing date of a first Office action on the merits. As a result, no fee should be required to file this IDS. However, if the Patent Office determines that a fee is required for Applicants to file this IDS, please charge any such fees, or credit overpayment, to Deposit Account No. 02-4550. A **duplicate** copy of this Information Disclosure Statement is enclosed.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP


By



Susan Alpert Siegel, Ph.D.
Registration No. 43,121

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446

cc: Docketing

	Attorney Docket Number	4239-67784-01
	Application Number	10/789,400
	Filing Date	February 27, 2004
	First Named Inventor	Collins
	Art Unit	1632
	Examiner Name	Not yet assigned

U.S. PATENT DOCUMENTS

NOT RECOMMENDED: This application was filed after June 30, 2003, copies of United States patents and United States published patent applications do not have to be provided to the Patent Office. This requirement of 37 C.F.R. § 1.98(a)(2)(i) has been waived by the United States Patent and Trademark Office pursuant to the Official Gazette Notice on August 5, 2003 (1276 OG 55).

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee
		2002/0155581	10/24/2002	Murphy et al.
		2003/0232326	12/18/2003	Fouchier et al.
		2004/0005544	01/08/2004	Fouchier et al.
		5,993,824	11/30/1999	Murphy et al.
		6,264,957	07/24/2001	Collins
		6,410,023	06/25/2002	Durbin et al.
		6,689,367	02/10/2004	Collins et al.
		6,713,066	03/30/2004	Collins et al.

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee
		WIPO	WO 97/12032 A1	03.04.1997	The Government of the United States of America
		WIPO	WO 98/02530 A1	22.01.1998	The Government of the United States of America
		WIPO	WO 98/53078 A1	26.11.1998	The Government of the United States of America
		WIPO	WO 00/61611 A3	19.10.2000	The Government of the United States of America
		WIPO	WO 00/61737 A2	19.10.2000	The Government of the United States of America

EXAMINER SIGNATURE:	DATE CONSIDERED:
<p>* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Attorney Docket Number		4239-67784-01
				Application Number		10/789,400
				Filing Date		February 27, 2004
				First Named Inventor		Collins
				Art Unit		1632
				Examiner Name		Not yet assigned
		WIPO	WO 01/03744 A2	18.01.2001	The Government of the United States of America	
		WIPO	WO 01/04320 A1	18.01.2001	The Government of the United States of America	
		WIPO	WO 01/04335 A2	18.01.2001	The Government of the United States of America	
		WIPO	WO 01/42445 A2	14.06.2001	The Government of the United States of America	
		WIPO	WO 02/057302 A2	25.07.2002	Viro-Clinics B.V.	
Examiner's Initials*	Cite No. (optional)	OTHER DOCUMENTS				
		Bailly et al., "A Recombinant Human Parainfluenza Virus Type 3 (PIV3) in Which the Nucleocapsid N Protein Has Been Replaced by That of Bovine PIV3 Is Attenuated in Primates," <i>J. Virol.</i> 74:3188-3195 (2000).				
		Baron and Barrett, "Rescue of Rinderpest Virus from Cloned cDNA," <i>J. Virol.</i> 71:1265-1271 (1997).				
		Bastien et al., "Sequence Analysis of the N, P, M and F Genes of Canadian Human Metapneumovirus Strains," <i>Virus Res.</i> 93:51-62 (2003).				
		Beeler and van Wyke Coelingh, "Neutralization Epitopes of the F Glycoprotein of Respiratory Syncytial Virus: Effect of Mutation Upon Fusion Function," <i>J. Virol.</i> 63:2941:2950 (1989).				
		Bermingham and Collins, "The M2-2 Protein of Human Respiratory Syncytial Virus is a Regulatory Factor Involved in the Balance Between RNA Replication and Transcription," <i>Proc. Natl. Acad. Sci. USA</i> 96:11259-11264 (1999).				
		Bukreyev et al., "Interferon γ Expressed by a Recombinant Respiratory Syncytial Virus Attenuates Virus Replication in Mice Without Compromising Immunogenicity," <i>Proc. Natl. Acad. Sci. USA</i> 96:2367-2372 (1999).				
		Bukreyev et al., "Recovery of Infectious Respiratory Syncytial Virus Expressing an Additional, Foreign Gene," <i>J. Virol.</i> 70:6634-6641 (1996).				
		Collins et al., "Production of Infectious Human Respiratory Syncytial Virus from Cloned cDNA Confirms an Essential Role for the Transcription Elongation Factor from the 5' Proximal Open Reading Frame of the M2 mRNA in Gene Expression and Provides a Capability for Vaccine Development," <i>Proc. Natl. Acad. Sci. USA</i> 92:11563-11567 (1995).				

EXAMINER SIGNATURE:	DATE CONSIDERED:
* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Attorney Docket Number	4239-67784-01
		Application Number	10/789,400
		Filing Date	February 27, 2004
		First Named Inventor	Collins
		Art Unit	1632
		Examiner Name	Not yet assigned
		Connors et al., "A Cold-Passaged, Attenuated Strain of Human Respiratory Syncytial Virus Contains Mutations in the F and L Genes," <i>Virology</i> 208:478-484 (1995).	
		Connors et al., "Respiratory Syncytial Virus (RSV) F, G, M2 (22K), and N Proteins Each Induce Resistance to RSV Challenge, but Resistance Induced by M2 and N Proteins is Relatively Short-Lived," <i>J. Virol.</i> 65:1634-1637 (1991).	
		Dimock and Collins, "Rescue of Synthetic Analogs of Genomic RNA and Replicative-Intermediate RNA of Human Parainfluenza Virus Type 3," <i>J. Virol.</i> 67:2772-2778 (1993).	
		Durbin et al., "Human Parainfluenza Virus Type 3 (PIV3) Expressing the Hemagglutinin Protein of Measles Virus Provides a Potential Method for Immunization Against Measles Virus and PIV3 in Early Infancy," <i>J. Virol.</i> 74:6821-6831 (2000).	
		Durbin et al., "Mutations in the C, D, and V Open Reading Frames of Human Parainfluenza Virus Type 3 Attenuate Replication in Rodents and Primates," <i>Virology</i> 261:319-330 (1999).	
		Durbin et al., "Recovery of Infectious Human Parainfluenza Virus Type 3 from cDNA," <i>Virology</i> 235:323-332 (1997).	
		Feller et al., "Comparison of Identical Temperature-Sensitive Mutations in the L Polymerase Proteins of Sendai and Parainfluenza3 Viruses," <i>Virology</i> 276:190-201 (2000).	
		Firestone et al., "Nucleotide Sequence Analysis of the Respiratory Syncytial Virus Subgroup A Cold-Passaged (cp) Temperature Sensitive (ts) cpts-248-404 Live Attenuated Virus Vaccine Candidate," <i>Virology</i> 225:419-422 (1996).	
		Haller et al., "A Single Amino Acid Substitution in the Viral Polymerase Creates a Temperature-Sensitive and Attenuated Recombinant Bovine Parainfluenza Virus Type 3," <i>Virology</i> 288:342-350 (2001).	
		Hardy and Wertz, "The Cys ₃ -His ₁ Motif of the Respiratory Syncytial Virus M2-1 Protein Is Essential for Protein Function," <i>J. Virol.</i> 74:5880-5885 (2000).	
		Hassett and Condit, "Targeted Construction of Temperature-Sensitive Mutations in Vaccinia Virus by Replacing Clustered Charged Residues with Alanine," <i>Proc. Natl. Acad. Sci. USA</i> 91:4554-4558 (1994).	
		He et al., "Recovery of Infectious SV5 From Cloned DNA and Expression of a Foreign Gene," <i>Virology</i> 237:249-260 (1997).	
		Hoffman and Banerjee, "An Infectious Clone of Human Parainfluenza Virus Type 3," <i>J. Virol.</i> 71:4272-4277 (1997).	

EXAMINER SIGNATURE:	DATE CONSIDERED:
<p>* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Attorney Docket Number	4239-67784-01
		Application Number	10/789,400
		Filing Date	February 27, 2004
		First Named Inventor	Collins
		Art Unit	1632
		Examiner Name	Not yet assigned
		Jin et al., "Respiratory Syncytial Virus That Lacks Open Reading Frame 2 of the M2 Gene (M2-2) Has Altered Growth Characteristics and Is Attenuated in Rodents," <i>J. Virol.</i> 74:74-82 (2000).	
		Jin et al., "Recombinant Human Respiratory Syncytial Virus (RSV) from a cDNA and Construction of Subgroup A and B Chimeric RSV," <i>Virology</i> 251:206-214 (1998).	
		Juhasz et al., "The Major Attenuating Mutations of the Respiratory Syncytial Virus Vaccine Candidate <i>cpts530/1009</i> Specify Temperature-Sensitive Defects in Transcription and Replication and a Non-Temperature-Sensitive Alteration in mRNA Termination," <i>J. Virol.</i> 73:5176-5180 (1999).	
		Juhasz et al., "The Temperature-Sensitive (<i>ts</i>) Phenotype of a Cold-Passaged (<i>cp</i>) Live Attenuated Respiratory Syncytial Virus Vaccine Candidate, Designated <i>cpts530</i> , Results from a Single Amino Acid Substitution in the L Protein," <i>J. Virol.</i> 71:5814-5819 (1997).	
		Kato et al., "The Paramyxovirus, Sendai Virus, V Protein Encodes a Luxury Function Required for Viral Pathogenesis," <i>EMBO J.</i> 16:578-587 (1997).	
		Kretzschmar et al., "Normal Replication of Vesicular Stomatitis Virus Without C Proteins," <i>Virology</i> 216:309-316 (1996).	
		Lambert et al., "Peptides from Conserved Regions of Paramyxovirus Fusion (F) Proteins are Potent Inhibitors of Viral Fusion," <i>Proc. Natl. Acad. Sci. USA</i> 93:2186-2191 (1996).	
		Lu et al., "Identification of Temperature-Sensitive Mutations in the Phosphoprotein of Respiratory Syncytial Virus That are Likely involved in Its Interaction with the Nucleoprotein," <i>J. Virol.</i> 76:2871-2880 (2002).	
		Newman et al., "Sequence Analysis of the Washington/1964 Strain of Human Parainfluenza Virus Type 1 (HPIV1) and Recovery and Characterization of Wild-Type Recombinant HPIV1 Produced by Reverse Genetics," <i>Virus Genes</i> . 24:77-92 (2002).	
		Peret et al., "Characterization of Human Metapneumoviruses Isolated from Patients in North America," <i>J. Infect. Dis.</i> 185:1660-1663 (2002).	
		Radecke and Billeter, "The Nonstructural C Protein is Not Essential for Multiplication of Edmonston B Strain Measles Virus in Cultured Cells," <i>Virology</i> 217:418-421 (1996).	
		Schmidt et al., "Bovine Parainfluenza Virus Type 3 (BPIV3) Fusion and Hemagglutinin-Neuraminidase Glycoproteins Make an Important Contribution to the Restricted Replication of BPIV3 in Primates," <i>J. Virol.</i> 74:8922-8929 (2000).	
		Skiadopoulos et al., "Determinants of the Host Range Restriction of Replication of Bovine Parainfluenza Virus Type 3 in Rhesus Monkeys are Polygenic," <i>J. Virol.</i> 77:1141-1148 (2003).	

EXAMINER SIGNATURE:	DATE CONSIDERED:
<p>* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Attorney Docket Number	4239-67784-01
		Application Number	10/789,400
		Filing Date	February 27, 2004
		First Named Inventor	Collins
		Art Unit	1632
		Examiner Name	Not yet assigned
		Skiadopoulos et al., "Generation of a Parainfluenza Virus Type 1 Vaccine Candidate by Replacing the HN and F Glycoproteins of the Live-Attenuated PIV3 cp45 Vaccine Virus With Their PIV1 Counterparts," <i>Vaccine</i> 18:503-510 (2000).	
		Skiadopoulos et al., "Attenuation of the Recombinant Human Parainfluenza Virus Type 3 cp45 Candidate Vaccine Virus is Augmented by Importation of the Respiratory Syncytial Virus cpts530 L Polymerase Mutation," <i>Virology</i> 260:125-135 (1999).	
		Skiadopoulos et al., "Identification of Mutations Contributing to the Temperature-Sensitive, Cold-Adapted, and Attenuation Phenotypes of the Live-Attenuated Cold-Passage 45 (cp45) Human Parainfluenza Virus 3 Candidate Vaccine," <i>J. Virol.</i> 73:1374-1381 (1999).	
		Skiadopoulos et al., "Three Amino Acid Substitutions in the L Protein of the Human Parainfluenza Virus Type 3 cp45 Live Attenuated Vaccine Candidate Contribute to Its Temperature-Sensitive and Attenuation Phenotypes," <i>J. Virol.</i> 72:1762-1768 (1998).	
		Tang et al., "Clustered Charge-to-Alanine Mutagenesis of Human Respiratory Syncytial Virus L Polymerase Generates Temperature-Sensitive Viruses," <i>Virology</i> 302:207-216 (2002).	
		Tang et al., "Requirement of Cysteines and Length of the Human Respiratory Syncytial Virus M2-1 Protein for Protein Function and Virus Viability," <i>J. Virol.</i> 75:11328-11335 (2001).	
		Tao et al., "Construction of a Live-Attenuated Bivalent Vaccine Virus Against Human Parainfluenza Virus (PIV) Types 1 and 2 Using a Recombinant PIV3 Backbone," <i>Vaccine</i> 19:3620-3631 (2001).	
		Tao et al., "A Live Attenuated Chimeric Recombinant Parainfluenza Virus (PIV) Encoding the Internal Proteins of PIV Type 3 and the Surface Glycoproteins of PIV Type 1 Induces Complete Resistance to PIV1 Challenge and Partial Resistance to PIV3 Challenge," <i>Vaccine</i> 17:1100-1108 (1999).	
		Tao et al., "Recovery of a Fully Viable Chimeric Human Parainfluenza Virus (PIV) Type 3 in Which the Hemagglutinin-Neuraminidase and Fusion Glycoproteins Have Been Replaced by Those of PIV Type 1," <i>J. Virol.</i> 72:2955-2961 (1998).	
		Teng et al., "Contribution of the Respiratory Syncytial Virus G Glycoprotein and its Secreted and Membrane-Bound Forms to Virus Replication In Vitro and In Vivo," <i>Virology</i> 289:283-296 (2001).	
		van den Hoogen et al., "Analysis of the Genomic Sequence of a Human Metapneumovirus," <i>Virology</i> 295:119-132 (2002).	

EXAMINER SIGNATURE:	DATE CONSIDERED:
<p>* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Attorney Docket Number	4239-67784-01
		Application Number	10/789,400
		Filing Date	February 27, 2004
		First Named Inventor	Collins
		Art Unit	1632
		Examiner Name	Not yet assigned
		van den Hoogen et al., "A Newly Discovered Human Pneumovirus Isolated from Young Children With Respiratory Tract Disease," <i>Nature Med.</i> 7:719-724 (2001).	
		van Wyke Coelingh and Tierney, "Antigenic and Functional Organization of Human Parainfluenza Virus Type 3 Fusion Glycoprotein," <i>J. Virol.</i> 63:375-382 (1989).	
		Wertman et al., "Systematic Mutational Analysis of the Yeast <i>ACT1</i> Gene," <i>Genetics</i> 132:337-350 (1992).	
		Whitehead et al., "Recombinant Respiratory Syncytial Virus Bearing a Deletion of Either the NS2 or SH Gene is Attenuated in Chimpanzees," <i>J. Virol.</i> 73:3438-3442 (1999).	
		Whitehead et al., "Addition of a Missense Mutation Present in the L Gene of Respiratory Syncytial Virus (RSV) <i>cpts530/1030</i> to RSV Vaccine Candidate <i>cpts248/404</i> Increases Its Attenuation and Temperature Sensitivity," <i>J. Virol.</i> 73:871-877 (1999).	
		Whitehead et al., "A Single Nucleotide Substitution in the Transcription Start Signal of the M2 Gene of Respiratory Syncytial Virus Vaccine Candidate <i>cpts248/404</i> is the Major Determinant of the Temperature-Sensitive and Attenuation Phenotypes," <i>Virology</i> 247:232-239 (1998).	
		Whitehead et al., "Recombinant Respiratory Syncytial Virus (RSV) Bearing a Set of Mutations from Cold-Passaged RSV is Attenuated in Chimpanzees," <i>J. Virol.</i> 72:4467-4471 (1998).	

EXAMINER
SIGNATURE:DATE
CONSIDERED:

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.